Tuesday 16 August 2022 - 02:53
PLEASE NOTE: During August 2022 we are doing a comprehensive revision of our customer service workflow. This includes training of current and new personnel. We are expecting that these changes will have only very minimal effects on our overall order processing and shipping activities. However, we do ask any customers who prefer that their shipments go out on Fridays to contact our Customer Service group and let them know about your preferences in advance. Thank you.
Reminder: Genuine LC Laboratories® brand PMA, which we have been manufacturing in the U.S. for more
than 40 years, is available directly from us: Cat No. P-1680 Phorbol 12-Myristate 13-Acetate, >99.5%.
Our PMA is also available from our >50 U.S. and international distributors, and from more than a dozen
major biochemical reagent "resellers" (who sell our PMA under their own brand names and labels)
FREE SHIPPING TO THE U.S. AND 32 OTHER COUNTRIES! [Read more].
T-8448 Torin 2, Free Base, >99%
Synonyms : [mTOR Inhibitor XII]
- Size
- US $
- €
- £
- ¥
- 5 mg
- 69
- 67
- 57
- 9,200
- In stock
- 10 mg
- 96
- 94
- 79
- 12,700
- In stock
- 25 mg
- 198
- 194
- 163
- 26,300
- In stock
- 50 mg
- 315
- 308
- 260
- 41,800
- In stock
- 100 mg
- 543
- 532
- 449
- 72,000
- In stock
- 250 mg
- 830
- 813
- 686
- 110,100
- In stock
Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.
- M.W. 432.40
- C24H15F3N4O
- [1223001-51-1]
Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO. Disposal: A.
- Torin 2 is a highly potent and selective ATP-competitive mammalian target of rapamycin (mTOR) kinase inhibitor. Torin 2 inhibited cellular mTOR activity with an IC50 of 0.25 nM and exhibited 800-fold selectivity over PI3K (IC50 = 200 nM) and over 100-fold binding selectivity over 440 other protein kinases. Liu Q., et al. "Discovery of 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer." J. Med. Chem. 54: 1473-1480 (2011).
- In addition to mTOR, torin 2 also exhibited potent biochemical and cellular activity against phosphatidylinositol-3 kinase-like (PI3K-like) kinase family kinases including ATM (IC50 = 28 nM), ATR (IC50 = 35 nM), and DNA-PK (IC50 = 118 nM), the inhibition of which sensitized cells to irradiation. Treatment with torin 2 for 24 hours resulted in strong growth inhibition of cancer cells in vitro. Single-agent treatment with torin 2 in vivo did not show significant efficacy against KRAS-driven lung tumors, but the combination of torin 2 with mitogen-activated protein/extracellular signal-regulated kinase inhibitor AZD6244 (selumetinib, please see Cat. No. S-4490, Selumetinib, Free Base) demonstrated a significant growth inhibition. Liu Q., et al. "Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR." Cancer Res. 73: 2574-2586 (2013).
- Torin 1 and torin 2 are potent antimalarials. Hanson K.K., et al. "Torins are potent antimalarials that block replenishment of Plasmodium liver stage parasitophorous vacuole membrane proteins." Proc. Natl. Acad. Sci. USA 110: E2838-E2847 (2013).
- Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use.
- This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
- Not available in some countries; not available to some institutions; not available for some uses.